If you're stacking GLP-1s with anything else, this is what worries him.

Dr. Abud Bakri has prescribed GLP-1s since he was a resident and seen patients lose 100 lb. The biggest worry now isn't the drug. It's what people are adding on top of it.

GLP-1s: Overdosing, Side Effects & Long-Term Risks | Dr. Abud Bakri & Dr. Andrew Huberman

Sam Altman said it out loud. He overdosed on a GLP-1. Not because he did the math wrong, he told an interviewer, but because a compounding pharmacy got the dosage wrong. What happened next was what a lot of people have described quietly: his food drive dropped, yes, but so did his drive, period.

Dr. Abud Bakri has heard the same thing from patients. He has been prescribing these drugs since he was a resident, putting 300 lb veterans on semaglutide and watching them lose 50, 100 lb before the FDA had approved it for weight loss. Bodybuilders figured it out first in the late 2010s. Pharma followed.

Now the question isn't whether GLP-1s work. It's whether people can stay on them safely, whether they need to stay on them forever, and what happens when they start stacking them with ADHD meds, peptide stimulants and everything else they buy from the same websites.

The medical system was about to collapse without them

Bakri says the obesity and diabetes epidemics were on track to break the US medical system. There were not enough clinicians, not enough money, not enough dialysis chairs for everyone who was pre-diabetic 20 years ago and sliding into full diabetes, cardiovascular disease and renal failure.

GLP-1s changed that math. For the first time, doctors had a drug that could take off 10, 20, even 30% of body weight. Older weight loss drugs barely managed 5 to 10%. Ideally everyone would get morning sunlight, eat unprocessed food and sleep great. But when people get stuck at 300 lb, Bakri says, stepping out the way you came in does not always work. You need a different path.

The drugs are here. Semaglutide is Ozempic for diabetes, Wegovy for weight loss. Tirzepatide is Mounjaro and Zepbound. The patents stay alive longer that way. Bakri is cautiously optimistic. So far the data is promising. The question is whether there is a free lunch.

We're in a post-GLP-1 world and everything kind of dictates downstream from that.Huberman Lab Clips

His grandma took the first version 25 years ago

GLP-1 was discovered in the saliva of Gila monsters. It was too short acting to use on its own. Pharma companies engineered longer lasting versions with extended half lives. Byetta was one of the first.

Bakri's grandmother took Byetta 25 years ago. It is the reason he went into medicine. Of all the drugs she was on, that was the one that changed her trajectory. She needed less insulin, lost weight, had more energy.

The effect showed up in diabetics first. Then it was tested in people who were overweight or obese without diabetes. The signal was clear. The long term effect is still the open question.

Pharma has not told you how to get off

The drug companies have shown what happens if you stop cold after maxing out your dose. Some people keep the weight off. Some gain it all back, right to baseline.

Bakri explains it as a calculation your brain does every day. Hormones from the gut, GIP, GLP, glucagon, insulin, testosterone, estrogen, all feed into a set point or settling point. The brain decides: eat or don't eat. GLP-1 is a giant signal to the brain that says don't eat.

What happens to an 18 year old on 5 mg of Retatrutide who has lost 40 lb? Are they on it for life now to maintain that weight? The pharma companies have not given clinicians good guidelines on titration off.

Why this matters if you haven’t started yet: If you are starting, ask your prescriber now what the exit plan is, even if you are months away from needing one.

The brain effects might not be from the drug

Zach Knight's lab at UCSF found that older diabetic GLP-1 drugs doubled or quadrupled GLP levels. The new weight loss drugs, Ozempic, Mounjaro, Zepbound and especially Retatrutide, increase GLP by a thousand fold or more.

Nobody knows what that does long term to neuroplasticity, learning or motivation. It could be positive. In 60 year olds with pre-diabetes, controlling insulin dynamics may protect against Alzheimer's. Obesity speeds up cognitive decline. A recent study did not show a strong Alzheimer's prevention signal, but the thinking is still evolving.

The question Bakri asks is whether the cognitive complaints, the depression, the lack of drive, are from the drug itself or from misuse. Too high a dose. Not enough electrolytes. Not enough food. Low blood sugar. Some people take a mega dose and go a whole day eating one meal. That is not conducive to feeling good.

The question is, are they just, you know, a lot of people have low blood pressure from these drugs because they're not consuming enough electrolytes or enough food period.Huberman Lab Clips

The training wheels approach keeps side effects low

Bakri's clinic uses what he calls a training wheels approach. Start with the lowest dose that has an effect. Pair the GLP-1 with lifestyle changes, dietary advice, exercise programs. Then either peel away the training wheels or keep them on until you hit the endpoint you want.

When patients do it that way, he does not hear the complaints that flood social media. No deep depression. No total loss of motivation. He thinks a lot of the online reports come from people who are not eating enough, not getting enough salt, not socializing because they are skipping meals.

Eating is a social experience. A lot of connection happens at the table. If you stop eating with people, are you losing that too? Bakri wonders if some of the mood effects are downstream consequences of reduced appetite, not direct brain effects.

Why this matters if you haven’t started yet: If you feel worse on a GLP-1, check your electrolytes, your total calories and how often you are eating with other people before you assume the drug is wrong.

People are stacking them with ADHD meds and peptides

There is evidence now that GLP-1s reduce alcohol cravings. That suggests the drugs may be changing dopaminergic signaling in the brain. That is concerning, Bakri says, because a lot of people are stacking GLP-1s with ADHD medications or peptide stimulants like Ipamorelin or others.

The pattern he sees: someone goes to a peptide website, buys one, gets a great result, then adds three more. The websites have an incentive. Average order value goes up when people add products. Nobody is tracking what happens when you layer a GLP-1 on top of a dopamine reuptake inhibitor on top of a growth hormone secretagogue.

Some people Bakri knows are taking much lower doses than prescribed and say they think better. That could be improved insulin sensitivity. It could be less body fat, which is an endocrine organ. It could be something else. Nobody knows if these are direct effects on the brain or indirect.

A lot of people will be stacking this with ADHD medications. They might be using some of these peptide stimulants. So the question is what happens.Huberman Lab Clips

Leptin sensitivity goes up as body fat goes down

There are GLP-1 receptors on POMC neurons in the brain. Nobody has fully examined what that means for the leptin melanocortin pathway, for energy status, thyroid hormone production or reproductive status.

A lot of women are having Ozempic babies. They were overweight or obese, subfertile or infertile, started a weight loss drug and found out by accident they were pregnant. Fertility improves as weight comes off because leptin status is a key driver of fertility.

If you are starving and leptin is low, you should not be fertile. If you have too much leptin and you are leptin resistant, the same thing. GLP-1s modulate both. A Science paper years ago showed that leptin hitting a certain threshold signals the onset of puberty in females. Bakri thinks that is still part of the picture: enough body fat signals enough resources to support reproduction.

Why this matters if you haven’t started yet: If you are a woman of childbearing age starting a GLP-1, plan your contraception now. Fertility can return faster than you expect.

Bakri has been writing GLP-1 prescriptions since before they were famous. He has seen them work. He has also seen people buy three more peptides the week after their first injection because the internet told them to stack.

The drug is not the risk. The risk is everything people do around it. Too high a dose because a compounding pharmacy got it wrong. Not enough food because the appetite suppression felt like permission to skip meals. A peptide stack nobody studied. A dropout plan nobody gave you. All of it is fixable, but only if you know to ask before the first injection.

Questions people ask

Do you have to stay on a GLP-1 for the rest of your life?

Pharma companies have not given clear guidelines on how to taper off. Some people regain all the weight after stopping, especially if they maxed out their dose and quit cold. Others maintain the loss. There is no standard exit protocol yet.

Can GLP-1s affect your brain or motivation long term?

The new weight loss GLP-1s increase GLP levels by a thousand fold or more. Nobody knows the long term effects on neuroplasticity or learning. Some cognitive complaints may be from low blood sugar, low electrolytes or not eating enough, not from the drug itself.

Is it safe to take a GLP-1 with ADHD medication or other peptides?

There is no good data on stacking GLP-1s with ADHD meds or other peptides. GLP-1s may change dopamine signaling in the brain, and combining them with stimulants or other compounds has not been studied in trials.

HL
Huberman Lab Clips

Dr. Abud Bakri is a physician who has prescribed GLP-1s since his residency, including to veterans at a VA clinic before the drugs were FDA approved for weight loss. 493,616 views on the original video.

Watch the original on YouTube →

Trending Topics